Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.03), Briefing.com reports. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.57%. The firm had revenue of $168.30 million during the quarter, compared to analyst estimates of $148.83 million. During the same period last year, the firm earned ($0.02) EPS. Supernus Pharmaceuticals’s quarterly revenue was up 24.1% on a year-over-year basis. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.
Supernus Pharmaceuticals Stock Performance
NASDAQ SUPN traded up $0.40 on Friday, reaching $31.88. The company had a trading volume of 13,171 shares, compared to its average volume of 481,451. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -108.24 and a beta of 0.90. Supernus Pharmaceuticals has a 1-year low of $21.99 and a 1-year high of $35.44. The company’s fifty day moving average is $27.93 and its 200-day moving average is $29.38.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Piper Sandler lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
- Five stocks we like better than Supernus Pharmaceuticals
- EV Stocks and How to Profit from Them
- Is Dell’s Stock Plunge a Once-in-a-Lifetime Buying Opportunity?
- 3 Tickers Leading a Meme Stock Revival
- Why Analysts Still Predict Double-Digit Upside for Mosaic Stock
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Novo Nordisk’s Shares Go on a Rollercoaster Ride After Earnings
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
